FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018255163> ?p ?o ?g. }

• W2018255163 endingPage "486" @default.
• W2018255163 startingPage "481" @default.
• W2018255163 abstract "1. Saturation experiments indicated that [3H]-yohimbine binding was specific, saturable and labelled a single population of sites in rat cerebral cortex (Kd 5.3 +/- 0.9 nM, Bmax 121 +/- 10 fmol mg-1 protein) and human platelets (Kd 0.7 +/- 0.1 nM, Bmax 152 +/- 10 fmol mg-1 protein). 2. The alpha 2-adrenoceptor antagonists, yohimbine, rauwolscine, WY 26703, idazoxan and BDF 6143 displaced [3H]-yohimbine binding to each tissue in a simple manner, with high affinity and Hill slopes close to unity. 3. The alpha 1-adrenoceptor agonist, oxymetazoline and the antagonist prazosin inhibited the binding of [3H]-yohimbine to rat in a complex manner consistent with an interaction at more than one site. However, indoramin and WB 4101 only appeared to interact with one site. In contrast, in human platelets, all antagonists gave rise to monophasic displacement curves with Hill slopes close to unity suggesting a single site of interaction. 4. The 5-hydroxytryptamine (5-HT) receptor ligands, 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), RU 24969, and methysergide inhibited the binding of [3H]-yohimbine to rat cortex with high and low affinity, consistent with an interaction with two populations of binding sites. However, inhibition of [3H]-yohimbine binding to human platelets suggested a single site of interaction. The low affinity of 5-HT, 5-carboxyamidotryptamine (5-CT) and dipropyl-5-CT indicated that [3H]-yohimbine was not labelling a 5-HT1-like site in rat cortex. 5. The ability of 8-OH-DPAT, RU 24969 and methysergide in addition to prazosin and oxymetazoline to differentiate [3H]-yohimbine binding provides additional pharmacological evidence for heterogeneity within rat cortical alpha 2-adrenoceptors. However, if the two sites in rat cortex that are differentiated by the 5-HT ligands represent (alpha 2A- and alpha 2B-adrenoceptor subtypes as defined by prazosin and oxymetazoline, then they do not correspond to the population of sites in human platelets. As receptor classification should be linked to affinity of drugs rather than tissue distribution, the current classification of alpha 2-adrenoceptor subtypes does not appear to be satisfactory." @default.
• W2018255163 created "2016-06-24" @default.
• W2018255163 creator A5002791765 @default.
• W2018255163 creator A5006330314 @default.
• W2018255163 creator A5011577349 @default.
• W2018255163 creator A5059319160 @default.
• W2018255163 creator A5080135978 @default.
• W2018255163 date "1990-03-01" @default.
• W2018255163 modified "2023-09-23" @default.
• W2018255163 title "Heterogeneity of α2-adrenoceptors in rat cortex but not human platelets can be defined by 8-OH-DPAT, RU 24969 and methysergide" @default.
• W2018255163 cites W1515631786 @default.
• W2018255163 cites W1775749144 @default.
• W2018255163 cites W1787051283 @default.
• W2018255163 cites W1910393924 @default.
• W2018255163 cites W1967325029 @default.
• W2018255163 cites W1988204563 @default.
• W2018255163 cites W1989854140 @default.
• W2018255163 cites W2003011863 @default.
• W2018255163 cites W2006913937 @default.
• W2018255163 cites W2009133356 @default.
• W2018255163 cites W2012335673 @default.
• W2018255163 cites W2012808016 @default.
• W2018255163 cites W2014740637 @default.
• W2018255163 cites W2020250790 @default.
• W2018255163 cites W2024709967 @default.
• W2018255163 cites W2041987085 @default.
• W2018255163 cites W2042706478 @default.
• W2018255163 cites W2043813981 @default.
• W2018255163 cites W2044938337 @default.
• W2018255163 cites W2046919916 @default.
• W2018255163 cites W2048378513 @default.
• W2018255163 cites W2056544132 @default.
• W2018255163 cites W2066507680 @default.
• W2018255163 cites W2074631079 @default.
• W2018255163 cites W2085210600 @default.
• W2018255163 cites W2086689515 @default.
• W2018255163 cites W2209337032 @default.
• W2018255163 cites W2282826323 @default.
• W2018255163 cites W2408148837 @default.
• W2018255163 cites W2468488662 @default.
• W2018255163 cites W1946891266 @default.
• W2018255163 doi "https://doi.org/10.1111/j.1476-5381.1990.tb12954.x" @default.
• W2018255163 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1917355" @default.
• W2018255163 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1970497" @default.
• W2018255163 hasPublicationYear "1990" @default.
• W2018255163 type Work @default.
• W2018255163 sameAs 2018255163 @default.
• W2018255163 citedByCount "33" @default.
• W2018255163 countsByYear W20182551632017 @default.
• W2018255163 countsByYear W20182551632019 @default.
• W2018255163 countsByYear W20182551632020 @default.
• W2018255163 crossrefType "journal-article" @default.
• W2018255163 hasAuthorship W2018255163A5002791765 @default.
• W2018255163 hasAuthorship W2018255163A5006330314 @default.
• W2018255163 hasAuthorship W2018255163A5011577349 @default.
• W2018255163 hasAuthorship W2018255163A5059319160 @default.
• W2018255163 hasAuthorship W2018255163A5080135978 @default.
• W2018255163 hasBestOaLocation W20182551631 @default.
• W2018255163 hasConcept C107824862 @default.
• W2018255163 hasConcept C126322002 @default.
• W2018255163 hasConcept C134018914 @default.
• W2018255163 hasConcept C170493617 @default.
• W2018255163 hasConcept C185592680 @default.
• W2018255163 hasConcept C2776504411 @default.
• W2018255163 hasConcept C2776885963 @default.
• W2018255163 hasConcept C2777676773 @default.
• W2018255163 hasConcept C2780648677 @default.
• W2018255163 hasConcept C2780939551 @default.
• W2018255163 hasConcept C2781005078 @default.
• W2018255163 hasConcept C2908647359 @default.
• W2018255163 hasConcept C55493867 @default.
• W2018255163 hasConcept C71924100 @default.
• W2018255163 hasConcept C86803240 @default.
• W2018255163 hasConcept C99454951 @default.
• W2018255163 hasConceptScore W2018255163C107824862 @default.
• W2018255163 hasConceptScore W2018255163C126322002 @default.
• W2018255163 hasConceptScore W2018255163C134018914 @default.
• W2018255163 hasConceptScore W2018255163C170493617 @default.
• W2018255163 hasConceptScore W2018255163C185592680 @default.
• W2018255163 hasConceptScore W2018255163C2776504411 @default.
• W2018255163 hasConceptScore W2018255163C2776885963 @default.
• W2018255163 hasConceptScore W2018255163C2777676773 @default.
• W2018255163 hasConceptScore W2018255163C2780648677 @default.
• W2018255163 hasConceptScore W2018255163C2780939551 @default.
• W2018255163 hasConceptScore W2018255163C2781005078 @default.
• W2018255163 hasConceptScore W2018255163C2908647359 @default.
• W2018255163 hasConceptScore W2018255163C55493867 @default.
• W2018255163 hasConceptScore W2018255163C71924100 @default.
• W2018255163 hasConceptScore W2018255163C86803240 @default.
• W2018255163 hasConceptScore W2018255163C99454951 @default.
• W2018255163 hasIssue "3" @default.
• W2018255163 hasLocation W20182551631 @default.
• W2018255163 hasLocation W20182551632 @default.
• W2018255163 hasLocation W20182551633 @default.
• W2018255163 hasLocation W20182551634 @default.
• W2018255163 hasOpenAccess W2018255163 @default.
• W2018255163 hasPrimaryLocation W20182551631 @default.
• W2018255163 hasRelatedWork W1812768215 @default.

• next